Avatrombopag hydrochloride

Overview

Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist ( EC 50 =3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Cardiovascular Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Thrombopoietin Receptor

Product Information

• Catalog No.: HY-13463B
• CAS No.: 570403-17-7
• Molecular Formula: C29H35Cl3N6O3S2
• Molecular Weight: 686.12
• Purity: 97.05%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 0.83 mg/mL (1.21 mM); Clear solution
• Availability: In-stock

Source

Original product source